Pasithea Therapeutics (KTTA) investor relations material

Opening remarks and agenda

• Meeting held virtually, allowing stockholders to exercise full rights as in-person attendees.

• Introductions included CEO, CFO, independent accountants, and corporate counsel.

• Agenda included voting on three proposals: election of directors, ratification of auditors, and a reverse stock split.

Corporate governance

• Record date for voting was July 24, 2026, with 33,414,448 shares outstanding, each entitled to one vote.

• Quorum confirmed, enabling the meeting to proceed with official business.

• Inspector of Elections appointed and proxies received in advance.

Board and executive committee updates

• Dr. Tiago Reis Marques and Professor Lawrence Steinman nominated as Class 3 directors to serve until 2029.

• No other director nominations were received.